Sat - Wed 8.30 - 16.00

+98 21 86085141

Number 21, Joibar Alley, Shad Street, Mollasadra Street , Tehran - Iran

Top
Home  /  Portfolio  /  Pharmaceutical  /  Xeomin  / 

Xeomin


* FDA approved in 2010 for use in the United States for cervical dystonia and blepharospasm in adults. * FDA approved in 2015 for use in the United States for upper limb spasticity in adults. * Approved in Europe for cervical dystonia and blepharospasm since 2005 and approved for post-stroke ULS in Europe since 2009. * Approved in Canada for cervical dystonia, blepharospasm, and ULS since 2009. * Used in 49 countries worldwide. * Studied in clinical trials worldwide, which involved: * More than 400 adult patients with upper limb spasticity,including patients who had been previously treated and patients who were new to neurotoxin therapy * Nearly 600 patients with cervical dystonia * Nearly 400 patients with blepharospasm

down